Nalaganje...
Ipilimumab: A potential immunologic agent in the treatment of metastatic castration-resistant prostate cancer
Immunotherapy has garnered an important place in the therapeutic landscape of treatment in prostate cancer since approval of sipuleucel-T. Ipilimumab is a checkpoint inhibitor that is currently approved for the treatment of advanced melanoma. In the June issue of Lancet Oncology, Kwon and colleagues...
Shranjeno v:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Landes Bioscience
2014
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4130722/ https://ncbi.nlm.nih.gov/pubmed/25046606 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.29928 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|